报价延迟最少15分钟:2026/08/17 16:45 EDT
盘后时段
|
||||
|
16.57 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.20/--
|
|
企业价值
205.53M
|
| 资产负债 |
|
每股账面净值
-0.10
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases. |
